Drug Profile
Rheumatoid arthritis vaccine - Immune Response BioPharma
Alternative Names: AI 201; AI 204; AI 205; IR 201; IR 501; IR 703; RAVAX; Zyvac-RALatest Information Update: 10 Jul 2019
Price :
$50
*
At a glance
- Originator Immune Response Corporation
- Developer Immune Response BioPharma
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Rheumatoid arthritis
Most Recent Events
- 10 Jul 2019 RAVAX™ vaccine is still in phase III trials for Rheumatoid arthritis in USA
- 18 May 2015 The vaccine is still in phase-III development for Rheumatoid arthritis in USA
- 04 Feb 2014 Ravax™ is still in phase III development for Rheumatoid arthritis in USA